ONCOMATRYX

ONCOMATRYX is a biopharmaceutical company developing novel Antibody-Drug Conjugates (ADCs) targeting the tumor microenvironment, specifically Cancer-Associated Fibroblasts (CAFs). Their lead product, OMTX705, is a first-in-class ADC targeting Fibroblast Activation Protein (FAP) and is currently in Phase Ib-II clinical trials. The company collaborates with universities, hospitals, and research centers in the US and Europe.

Buy Funded Startups lists

Funding Round:

Funding Amount: €25M

Date: 27-Jan-2025

Investors: Existing investors, Centro para el Desarrollo Tecnológico y la Innovación

Markets: Biopharmaceutical, Oncology, Antibody-Drug Conjugates (ADCs)

HQ: Derio, Bizkaia, Spain

Founded: 2009

Website: https://oncomatryx.com/

LinkedIn: https://www.linkedin.com/company/oncomatryx-biopharma

Twitter: https://twitter.com/oncomatryx

Instagram: